Response to Comment on: Sun et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. Diabetes Care 2011;34:968–974

The Harvard community has made this article openly available.

Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.2337/dc11-1188</td>
</tr>
<tr>
<td>Accessed</td>
<td>August 23, 2017 10:02:45 AM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:10482551">http://nrs.harvard.edu/urn-3:HUL.InstRepos:10482551</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
Response to Comment on: Sun et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. Diabetes Care 2011;34:968–974

We thank Conway et al. (1) for the discussion of their findings regarding skin intrinsic fluorescence in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study cohort. Their results—that skin intrinsic fluorescence values are higher in individuals with no diabetic retinopathy (DR) as compared with more advanced DR—are consistent with our findings in the Medalist cohort in which increased concentrations of certain advanced glycation end products (carboxymethyl-lysine [CML] and the early glycation product fructose-lysine in the Medalists) were associated with protection from proliferative DR. Our findings of an inverse relationship between CML levels and proliferative retinopathy may suggest low levels of endothelial or inflammatory cell receptor for advanced glycation end product expression or activation (2) in response to its ligand CML in these participants.

In contrast to the Medalist group in which no difference in glycemic control was found between those with and without proliferative DR, the EDC participants without DR had better glycemic control than those with DR. This difference may reflect the fact that the EDC population had a shorter average duration of diabetes than the Medalists (41 vs. 57 years) and thus may have a lower percentage of participants with elevated protective factors against complications. Nonetheless, this report further confirms the existence of a subgroup of individuals who appear to be highly protected against the detrimental effects of chronic hyperglycemia and supports additional characterization of this unique population in hopes of identifying novel protective factors against retinopathy and other microvascular complications of diabetes.

Jennifer K. Sun, MD, MPH1,2,3
Hillary A. Keenan, PhD3,4

Vincent M. Monnier, MD5
Lloyd Paul Aiello, MD, PhD1,2,3
George L. King, MD3,4

From the 1Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts; the 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; the 3Research Division, Joslin Diabetes Center, Boston, Massachusetts; the 4Department of Internal Medicine, Harvard Medical School, Boston, Massachusetts; and the 5Departments of Pathology and Biochemistry, Case Western Reserve University, Cleveland, Ohio. Corresponding author: George L. King, george.king@joslin.harvard.edu.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

References